Results 11 to 20 of about 17,592 (206)

Updates on managing advanced breast cancer with palbociclib combination therapy

Therapeutic Advances in Medical Oncology, 2018
Background: The objective of this study was to review the pharmacology, efficacy, and safety of palbociclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of advanced breast cancer (ABC).
Teresa M. McShane, Thomas A. Wolfe, Joanne C. Ryan   +2 more
doaj   +2 more sources

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance [PDF]

Cancer Biology & Medicine, 2019
Objective Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zheng Wei Wong, Iuan Sheau Chin, Pei San Yee, Chai Phei Gan, Kein Seong Mun, Zainal Ariff Abdul Rahman, J. Silvio Gutkind, Vyomesh Patel, Sok Ching Cheong   +10 more
doaj   +2 more sources

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Current Issues in Molecular Biology
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor and a commonly used antitumor drug. Many cancers are susceptible to palbociclib resistance, however, the underlying metabolism mechanism and extent of resistance to palbociclib are unknown.
Lulu Yang, Yajun Yue, Zhendong Wang, You Jiang, Zhichao Xue, Yongzhuo Zhang   +5 more
doaj   +2 more sources

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

PLoS ONE, 2019
The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li, Xuehong Zhang, Liankun Gu, Jing Zhou, Dajun Deng   +4 more
doaj   +2 more sources

TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2/SLC7A11 expression

Cell Death Discovery
Palbociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer by suppressing cell proliferation. However, monotherapy with palbociclib was discouraging in prostate cancer, calling for a mechanism-based effective therapy. In this study, we
Yangyi Zhang, Chenyu Liu, Yalan Yang, He Ren, Tianyi Ren, Yinuo Huang, Shinan Zhang, Qiang Sun, Hongyan Huang   +8 more
doaj   +2 more sources

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models [PDF]

Molecular Therapy: Nucleic Acids, 2022
Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT ...
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini   +9 more
doaj   +2 more sources

In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments

Drug Design, Development and Therapy
Wenyu Du,1,2 Zihan Liu,1,2,* Ying Li,2,* Zhi Wang,2 Zhanjun Dong2 1Graduate School, Hebei Medical University, Shijiazhuang, 050017, People’s Republic of China; 2Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy ...
Du W, Liu Z, Li Y, Wang Z, Dong Z
doaj   +2 more sources

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Purpose Prevalence of breast cancer (BC) increases with age, but the external validity of data obtained from pivotal trials of medicinal products remains a concern due to the underrepresentation of frail and older adults. Cyclin‐dependent kinase inhibitors (CDKi), palbociclib, abemaciclib, and ribociclib are considered an essential part of the
Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, Hartikainen S, Tolppanen AM.   +7 more
europepmc   +2 more sources

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer

Zhongliu Fangzhi Yanjiu, 2022
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.
ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng   +5 more
doaj   +1 more source

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma [PDF]

, 2020
Background: Recent genomic analyses revealed that druggable molecule targets were only detectable in approximately 6% of patients with nasopharyngeal carcinoma (NPC).
You, C, Cheung, LWT, Lo, KW, Tsao, SW, YUAN, H, XUE, Z, Jia, L, Lee, VHF, Khong, PL, Lee, AWM, Tsang, CM, Piao, W, Li, Y, Li, X, Lui, VWY   +14 more
core   +1 more source